Thyroid Cancer

On this page

Intro & Risks - Gland Gone Wild

Thyroid Cancer Location Diagram

  • Most common endocrine malignancy; incidence ↑, especially in women.
  • Major Types:
    • Papillary (MC, 80-85%), Follicular (10-15%), Medullary (~3-5%), Anaplastic (<2%, worst prognosis).
    • 📌 Poor Fat Mice Always (Papillary, Follicular, Medullary, Anaplastic).
  • Key Risk Factors:
    • Radiation exposure: Childhood/adolescent head & neck (e.g., for lymphoma). Dose-dependent.
    • Family Hx/Genetic Syndromes:
      • Medullary: MEN2A/2B (RET proto-oncogene), Familial Medullary Thyroid Cancer (FMTC).
      • Papillary: Familial Adenomatous Polyposis (FAP), Gardner syndrome, Cowden syndrome (PTEN gene).
    • Iodine deficiency: ↑ risk for Follicular cancer.
    • Chronic TSH stimulation (e.g., Hashimoto's thyroiditis - controversial for papillary; established link to thyroid lymphoma).

⭐ Thyroid cancer is the most common endocrine malignancy. Papillary thyroid cancer (PTC) is its most prevalent subtype, often with an excellent prognosis if detected early and managed appropriately.

  • Papillary Carcinoma (PTC): ~80-85%.
    • Path: Orphan Annie eye nuclei (intranuclear inclusions, grooves), psammoma bodies.
    • Spread: Lymphatic. Prognosis: Excellent.
    • Variants: Follicular, Tall cell (worse prognosis).

    ⭐ Papillary thyroid cancer: most common type, psammoma bodies, excellent prognosis.

  • Follicular Carcinoma (FTC): ~10-15%.
    • Path: Capsular/vascular invasion essential for diagnosis (FNAC cannot diagnose).
    • Spread: Hematogenous (bone, lung). 📌 "Follicular Follows Vessels."
    • Hürthle cell variant: more aggressive.
  • Medullary Carcinoma (MTC): ~3-5%.
    • Origin: Parafollicular C-cells. Secretes calcitonin.
    • Path: Amyloid stroma (Congo red positive).
    • Associations: MEN 2A/2B (RET mutation).
  • Anaplastic Carcinoma (ATC): <1-2%.
    • Undifferentiated, highly aggressive. Often elderly.
    • Prognosis: Dismal, rapidly fatal.
  • Lymphoma: Rare. Often arises in Hashimoto's thyroiditis.

Medullary Thyroid Carcinoma: Key Histologic Findings

Diagnosis & Staging - Detective Work

Ultrasound features of malignant thyroid nodules

  • Clinical Evaluation: Neck swelling, hoarseness, dysphagia. Family Hx (Medullary Ca).
  • Thyroid Function Tests (TFTs): Usually euthyroid. TSH (suppressed in hot nodule, ↑ in Hashimoto's).
  • Ultrasound (USG) Neck: Initial imaging. High-risk features: solid, hypoechoic, microcalcifications, irregular margins, taller-than-wide, extrathyroidal extension, suspicious lymph nodes.
  • Fine Needle Aspiration Cytology (FNAC):

    ⭐ Fine Needle Aspiration Cytology (FNAC) is the gold standard investigation for a thyroid nodule.

    • Bethesda System for Reporting Thyroid Cytopathology (BSRTC) guides management.
  • Staging (AJCC 8th Ed): TNM. Age is key for Differentiated Thyroid Cancer (DTC).
    • Papillary/Follicular: Age <55 yrs (Stage I/II). Age ≥55 yrs (Stage I-IV).
    • Medullary: Calcitonin/CEA levels for prognosis & follow-up.
    • Anaplastic: All Stage IV (universally poor prognosis).

Management & Follow-up - Battle Plan

  • Primary Treatment
    • Surgery: Total Thyroidectomy (TT) ± Central/Lateral Neck Dissection. Lobectomy for select low-risk (e.g., unifocal papillary microcarcinoma $<$1cm, no ETE/mets).
  • Adjuvant Therapy (Risk-Stratified)
    • Radioactive Iodine (RAI; I-131): Post-TT for remnant ablation/adjuvant. Dose: 30-150 mCi.
    • TSH Suppression: Levothyroxine. Goal: TSH $<$0.1 mU/L (high-risk), 0.1-0.5 mU/L (low/intermediate-risk).

    ⭐ TSH suppression therapy is crucial post-thyroidectomy for differentiated thyroid cancer (DTC) to reduce recurrence.

  • Advanced/Recurrent Disease
    • EBRT: Unresectable, mets (bone, brain).
    • TKIs (Lenvatinib, Sorafenib): RAI-refractory DTC.
  • Follow-up (Dynamic Risk Assessment)
    • Serum Tg, Anti-TgAb, TSH (q 6-12 months).
    • Neck Ultrasound (q 6-12 months).
    • Further imaging (CT, MRI, PET) as indicated.

Postoperative DTC Management and Follow-up

High‑Yield Points - ⚡ Biggest Takeaways

  • Papillary Thyroid Carcinoma (PTC): Most common, excellent prognosis, psammoma bodies, lymphatic spread.
  • Follicular Carcinoma: Hematogenous spread (bone, lungs); FNAC cannot diagnose invasion (histology needed).
  • Medullary Carcinoma: From C-cells, produces calcitonin, linked to MEN2 (RET oncogene), amyloid stroma.
  • Anaplastic Carcinoma: Elderly patients, worst prognosis, rapidly aggressive and often fatal.
  • FNAC is the best initial diagnostic test for evaluating suspicious thyroid nodules.
  • Differentiated cancers (PTC, Follicular): Treat with total thyroidectomy, radioiodine ablation, TSH suppression.

Practice Questions: Thyroid Cancer

Test your understanding with these related questions

What is the most common thyroid tumor associated with multiple endocrine neoplasia (MEN)?

1 of 5

Flashcards: Thyroid Cancer

1/10

What is the next step in management when a whole-body iodine [I123] scan is positive after a total thyroidectomy for any differentiated thyroid cancer (papillary or follicular carcinoma)?_____

TAP TO REVEAL ANSWER

What is the next step in management when a whole-body iodine [I123] scan is positive after a total thyroidectomy for any differentiated thyroid cancer (papillary or follicular carcinoma)?_____

Radio-iodine ablation [I131]

browseSpaceflip

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

Start Your Free Trial